Thymosin Beta-4 (TB4) is a 43-amino-acid peptide that occurs naturally in virtually all mammalian cells, with the highest concentrations found in platelets and wound fluid. TB-500 is a synthetic fragment corresponding to an active region of TB4 and has been studied extensively for its role in tissue regeneration, cellular migration, and angiogenesis [1].

Biological Role

Thymosin Beta-4 is the primary G-actin-sequestering molecule in eukaryotic cells. By regulating the actin cytoskeleton, TB4 controls cell shape, motility, and proliferation, all of which are essential components of wound healing and tissue repair [2].

In wound environments, TB4 is released from platelets and participates in the earliest stages of repair. It has been documented to promote:

• Cell migration toward injured tissue
• Formation of new blood vessels (angiogenesis)
• Reduced inflammation and apoptosis
• Collagen deposition and dermal remodeling
• Survival of endothelial and cardiac cells under stress

Thymosin Beta-4 and its active fragment TB-500 promote endothelial cell migration, angiogenesis, and dermal remodeling in preclinical wound models.

— Local and Systemic Peptide Therapies for Soft Tissue Regeneration, PMC11426299 (2024)

Research Context

TB4 has been evaluated in preclinical and early clinical studies across ischemic tissue, corneal wounds, cardiac injury models, and chronic skin ulcers. Early-phase trials investigated its use in pressure ulcers, epidermolysis bullosa, and dry eye syndrome [3].

Like BPC-157, TB-500 is frequently studied in musculoskeletal injury models. It is also on the World Anti-Doping Agency prohibited list and is not approved by the U.S. Food and Drug Administration for therapeutic use.

Combination Research

An active area of preclinical investigation involves combinations of BPC-157 with Thymosin Beta-4 or TB-500. The rationale is that the two peptides engage complementary pathways: BPC-157 supports angiogenesis via VEGFR2, while TB-500 drives cellular migration and cytoskeletal organization [4].

References

[1] Goldstein A.L., Hannappel E., Kleinman H.K. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429.

[2] Crockford D., Turjman N., Allan C., Angel J. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci. 2010;1194:179-189.

[3] Kleinman H.K., Sosne G. Thymosin β4 Promotes Dermal Healing. Vitam Horm. 2016;102:251-275.

[4] Local and Systemic Peptide Therapies for Soft Tissue Regeneration: A Narrative Review. PMC11426299 (2024).